Famciclovir sustained-release dropping pill and preparation method thereof

Abstract

The invention discloses an antivirus drug compound and particularly relates to an oral pharmaceutical preparation adopting famciclovir as the ingredient and being prepared jointly with the medicinal carrier used as the stroma. The antivirus drug compound aims to supplement the deficiency of the prior antivirus oral pharmaceutical preparation and provide a sustained-release famciclovir dropping pill which has high bioavailability, fast effect, high drug content, low frequency of drug taking, full release, convenient drug taking, low cost and absence of contamination during the production. The sustained-release famciclovir dropping pill adopts famciclovir as the ingredient and is prepared jointly with the medicinal carriers of mixing hydrophilic frame ingredients and hydrophobic frame ingredients as the stroma.

Description

technical field [0001] The invention relates to an antiviral pharmaceutical composition, in particular to an oral preparation prepared by taking famciclovir as a raw material, mixing a hydrophilic skeleton material and a hydrophobic skeleton material as a matrix and a pharmaceutically acceptable carrier. Background technique [0002] Famciclovir (famciclovir: FCV), the chemical name is 2-[2-(2-amino-9H-purin-9-yl)ethyl]-1,3-propanedioate. The chemical structural formula of famciclovir is as follows: [0003] [0004] Famciclovir (Famciclovir; Fcv) is a second-generation open-ring nucleoside anti-herpes virus drug, which is a guanosine nucleoside analogue. It was synthesized and developed by Harnden in 1985 and successfully developed by SmithKline-Beecham in the United Kingdom. It was first listed in the UK in 1993 and was approved by the US FDA in 1994 for the treatment of acute herpes zoster virus. It was approved for use in the United States after 1997. Its additional...

AI Technical Summary

Problems solved by technology

[0008] At present, famciclovir has oral dosage forms such as tablets. After oral administration of famciclovir tablets, the plasma concentration changes greatly. No matter for single antiviral therapy or combined antiviral therapy, this change is very unfavorable. It is necessary to develop a new dosage form of famciclovir for the current situation of good medicine for treating hepatitis B

[0009] In addition, oral dosage forms such as tablets, due to the preparation technology and other reasons, have problems such as long dissolution time, low dissolution rate, poor absorption, many times of taking medicine, hepatic and intestinal first-pass effect and low bioavailability after taking, which affect the medicine. Efficacy, also directly affects the effect of treatment

It is not suitable for children and the elderly, and for children, it is not accurate enough to take the dose when taking it.

Due to the granulation process in the tablet preparation process, large dust pollution will be generated, which will cause harm to the health of the staff to a certain extent, and will also cause certain pollution to the environment

Images